Navigation Links
BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico
Date:2/23/2012

uytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. XIAPEX is currently marketed in nine European and Eurasian markets: Austria, Denmark, Finland, Germany, Norway, Spain, Switzerland, Sweden, and the United Kingdom. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, expected revenue growth, and the assumptions underlying or relating to such statements, are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "anticipate," "plan," "estimate," "likely," "may," "will," "could," "continue," "project," "predict", "goal," the negative or plural of these words, and other similar expressions. Our forward-looking statements are only predictions based on our current expectations and our projections about future events. There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including the statements made by us and by our partner Auxilium Pharmaceuticals, Inc. ("Auxilium") regarding progress toward achievement
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
3. BioSpecifics Technologies Corp. Reports Second Quarter 2011 Financial Results
4. BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program
5. BioSpecifics Technologies Corp. to Present at Jefferies 2011 Global Healthcare Conference
6. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
7. BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU
8. BioSpecifics Technologies Corp. to Present at SEVEN, Noble Financial Capital Markets Seventh Annual Equity Conference
9. BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytrens Contracture in Europe
10. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
11. BioSpecifics Technologies Corp. Amends Its Rights Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... Colo. , Nov. 25, 2014 /PRNewswire/ ... ) today announced that its Chief Executive ... at the following upcoming conferences.  The public ... through webcasts on the Array BioPharma website:  ... December 3, 2014Time:1:30 p.m.  Eastern Time Location: ...
(Date:11/26/2014)... , Nov. 25, 2014 Amgen (NASDAQ: ... today announced that AMAGINE-2 TM , a pivotal, multi-arm Phase ... 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints ... at week 12. Brodalumab 210 mg given every two weeks ... be superior to Stelara on the primary endpoint of achieving ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... Minn., March 10 Here are highlights from the March ... cite this publication as often as you wish. Reprinting is ... attribution is required. Include the following ... www.HealthLetter.MayoClinic.com or call toll-free for subscription ...
... Avineuro Pharmaceuticals, Inc. announced today an initiation of ... selective small molecule antagonist of 5-HT6 receptor for treatment ... expected to be available in April 2009. Based on ... advance AVN-211 into Phase II clinical trials in Q2 ...
Cached Medicine Technology:March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 2March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 3March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 4March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 5
(Date:11/27/2014)... New Albany, IN (PRWEB) November 27, 2014 ... dental implant clinic, has a few oral health tips ... Dr. Receveur, who offers Louisville and New Albany affordable ... mountains of foods high in starch and sugar. While the ... practice has some helpful tips for how patients can enjoy ...
(Date:11/27/2014)... Burnsville MN (PRWEB) November 27, 2014 ... manufacturer of office ergonomics equipment , has announced ... partnership with Commercial Office Environments. The partnership will ... for office furnishings location. , In addition to ... the new dealer partnership promotes HealthPostures' products with ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Allowing children to ... even during school, helps give children responsibility, ownership, boosts self-esteem, ... , Now, the real question is, how do ... a secret? According to a study published by Child Development ... have a dramatic effect on a child’s willingness to lend ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. ... of laughter as we enjoy the ugly sweater contest." ... from scratch. " It was a sight to see. ... ridiculous enough, the Christmas balls were faces of the staff ... in participating this year, it's simple to get in on ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, ... announced online reputation management service. , The ... study about the world of internet marketing and algorithms ... , Ethane Web Technologies does not work with ... analyzes the project to reach a conclusion what will ...
Breaking Medicine News(10 mins):Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces Online Reputation Management Service 2
... a waiting list, can reduce problems with recurring low back ... Many people suffer with low back pain, and most ... find that their work, everyday and leisure activities are limited ... treatment, it is important that the pain be treated at ...
... Food and Drug Administration (FDA) approval of a brain aneurysm ... Jefferson Hospital for Neuroscience (JHN) to offer advanced ... otherwise have limited, effective options. "With this FDA approval, ... tool to block and shrink these types of aneurysms, saving ...
... Indiana soon will partner with colleagues in Ohio ... working across state lines to advance research on ... program, supported by the Indiana Clinical and Translational ... across the region, including Indiana University Health Riley ...
... Prozac: new drug offers hope for depression ... from depression, and though the symptoms might be ... incompletely understood. Research suggests that aberrant signaling by ... its receptor TrkB, may contribute to anxiety and ...
... Vancouver,s Downtown Eastside dropped by 35 per cent after ... facility, according a new study by researchers at the ... for Excellence in HIV/AIDS. Published today in The ... assess the impact of supervised injection sites on overdose ...
... Psychologists are offering new insight and solutions ... with the environmental, economic and health impacts already taking ... issue of American Psychologist , the American Psychological ... for and in many cases is already affecting ...
Cached Medicine News:Health News:Immediate treatment can alleviate future back problems 2Health News:FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool 2Health News:Children's doctors team up across state lines to fight disease 2Health News:JCI online early table of contents: April 18, 2011 2Health News:JCI online early table of contents: April 18, 2011 3Health News:JCI online early table of contents: April 18, 2011 4Health News:JCI online early table of contents: April 18, 2011 5Health News:JCI online early table of contents: April 18, 2011 6Health News:JCI online early table of contents: April 18, 2011 7Health News:Overdose deaths down 35 percent after opening of Vancouver's supervised injection site: UBC-BC-CfE study 2Health News:Climate change psychology: Coping and creating solutions 2Health News:Climate change psychology: Coping and creating solutions 3
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: